heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer - Kuemmel S.; Harper-Wynne C.; Park Y. H.; Franke F.; de Laurentiis M.; Schumacher-Wulf E.; Eiger D.; Heeson S.; Cardona A.; Ozyilkan O.; Morales-Vasquez F.; Metcalfe C.; et al. (BMC Cancer, 2024)